Close Menu

NEW YORK – Quest Diagnostics on Wednesday raised its full-year 2020 revenue guidance to at least $9.35 billion, up from a previous guidance of $8.8 billion to $9.1 billion.

The company attributed the raise to higher than anticipated SARS-CoV-2 molecular testing volumes.

"Since the company reported its financial performance for the third quarter of 2020 … COVID-19 molecular testing volumes have been significantly higher than the previous outlook contemplated," the Secaucus, New Jersey-based firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.